Q32 Bio Inc. (GETTEX:DB0) Financings

Q32 Bio Inc.

Financings

RaiseDate
Public offering of common stock and pre-funded warrants
Closed: US$200M raised · US$18.25 a share · Morgan Stanley +4
Dealers: Morgan Stanley (co-lead), Jefferies (co-lead), Cantor (co-lead), Oppenheimer & Co., H.C. Wainwright & Co.
Use of proceeds: With existing cash, fund operations through topline Phase 3 results of the planned registration-directed bempikibart program in severe or very severe AA
Aug 5, 2026
At-the-market programme of common stock
Tranche closed: US$14.2M raised
May 5, 2026
Registered direct offering of common stock and pre-funded warrants
Announced: US$10.5M · US$3.9 a share
Use of proceeds: Working capital, including research, clinical development and commercialization, and advancing bempikibart into future alopecia areata trials
Feb 17, 2026

Read by 6ix AI from the company's releases